Comparative effectiveness of upadacitinib versus ustekinumab in patients with moderately to severely active Crohn's disease: a matching-adjusted indirect comparison

被引：0
|
作者：
Ma, C. [1 ]
Dubinsky, M. C. [2 ]
Axelrad, J. [3 ]
Anyanwu, S. [4 ]
Tran, J. [5 ,6 ]
Lacerda, A. [4 ]
Joshi, N. [4 ]
Griffith, J. [4 ]
机构：
[1] Univ Calgary, Dept Med, Inflammatory Bowel Dis Clin, Calgary, AB, Canada
[2] Icahn Sch Med Mt Sinai, Div Pediat Gastroenterol & Nutr, New York, NY USA
[3] NYU Grossman Sch Med, Div Gastroenterol, Dept Med, New York, NY USA
[4] AbbVie Inc, Chicago, IL USA
[5] AbbVie Inc, Seattle, WA USA
[6] Univ Washington, Comparat Hlth Outcomes Policy & Econ Inst, Seattle, WA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1040
引用
收藏
页码：I1866 / I1867
页数：2
相关论文
共 50 条
  • [41] SECUKINUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: COMPARATIVE EFFECTIVENESS RESULTS VERSUS ADALIMUMAB USING A MATCHING-ADJUSTED INDIRECT COMPARISON
    Maksymowych, W.
    Strand, V
    Baeten, D.
    Nash, P.
    Thom, H.
    Hunger, M.
    Gandhi, K.
    Richards, H.
    Jugl, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : 782 - 782
  • [42] SECUKINUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: COMPARATIVE EFFECTIVENESS RESULTS VERSUS ADALIMUMAB USING A MATCHING-ADJUSTED INDIRECT COMPARISON
    Maksymowych, W.
    Strand, V.
    Baeten, D.
    Nash, P.
    Thom, H.
    Cure, S.
    Palaka, E.
    Gandhi, K.
    Richards, H.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 98 - 98
  • [43] Safety of Ustekinumab With and Without Concomitant Corticosteroids or Immunosuppressants in Patients With Moderately to Severely Active Crohn's Disease
    Sands, Bruce E.
    Gasink, Christopher
    Jacobstein, Douglas
    Ott, Elyssa
    Lang, Yinghua
    Ramachandran, Paraneedharan
    Ghosh, Subrata
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S329 - S330
  • [44] Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
    Mease, Philip J.
    Warren, Richard B.
    Nash, Peter
    Grouin, Jean-Marie
    Lyris, Nikos
    Willems, Damon
    Taieb, Vanessa
    Eells, Jason
    Mcinnes, Iain B.
    RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 817 - 828
  • [45] Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison
    Nash, Peter
    McInnes, Iain B.
    Mease, Philip J.
    Thom, Howard
    Hunger, Matthias
    Karabis, Andreas
    Gandhi, Kunal
    Mpofu, Shephard
    Jugl, Steffen M.
    RHEUMATOLOGY AND THERAPY, 2018, 5 (01) : 99 - 122
  • [46] COMPARISON OF PEDIATRIC PATIENTS AND YOUNG ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE TREATED WITH USTEKINUMAB IN THE REALITI REAL-WORLD EVIDENCE EFFECTIVENESS STUDY
    Steiner, Steven
    Saeed, Shezad A.
    Adler, Jeremy
    Colletti, Richard B.
    Strauss, Richard
    Heile, J. M.
    Adedokun, Omoniyi J.
    Sheahan, Anna
    Zhang, Renping
    Lo, Kim H.
    Kim, Lilianne
    Xiao, Yongling
    Volger, Sheri
    GASTROENTEROLOGY, 2024, 166 (05) : S1208 - S1208
  • [47] Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison
    Peter Nash
    Iain B. McInnes
    Philip J. Mease
    Howard Thom
    Matthias Hunger
    Andreas Karabis
    Kunal Gandhi
    Shephard Mpofu
    Steffen M. Jugl
    Rheumatology and Therapy, 2018, 5 : 99 - 122
  • [48] Comparison of Paediatric Patients and Young Adults with Moderately to Severely Active Crohn's Disease Treated with Ustekinumab in the REALITI Real-World Evidence Effectiveness Study
    Steiner, S.
    Shehzad, S.
    Adler, J.
    Colletti, R. B.
    Strauss, R.
    Heile, J.
    Adedokun, O.
    Sheahan, A.
    Zhang, R.
    Lo, K. H.
    Kim, L.
    Xiao, Y.
    Volger, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1729 - I1731
  • [49] Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Gasink, Christopher
    Kowalski, Ken
    Sandborn, William J.
    Feagan, Brian
    CLINICAL THERAPEUTICS, 2022, 44 (10) : 1336 - 1355
  • [50] Safety of Ustekinumab With and Without Concomitant Corticosteroids or Immunosuppressants in Patients With Moderately-to-Severely Active Crohn's Disease
    Bruce, Sands
    Christopher, Gasink
    Douglas, Jacobstein
    Elyssa, Ott
    Lang Yinghua
    Paraneedharan, Ramachandran
    Subrata, Ghosh
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S24 - S24
12345